NATURE’S SUNSHINE PRODUCTS, INC. Payments for Restructuring
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Payments for Restructuring of $594.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2022-03-08
- NATURE’S SUNSHINE PRODUCTS, INC. payments for restructuring for fiscal 2021 was $594.00K, a 29.29% decline from fiscal 2020.
- NATURE’S SUNSHINE PRODUCTS, INC. payments for restructuring for fiscal 2020 was $840.00K, a 62.78% decline from fiscal 2019.
- NATURE’S SUNSHINE PRODUCTS, INC. payments for restructuring for fiscal 2019 was $2.26M, a 12.40% increase from fiscal 2018.
- NATURE’S SUNSHINE PRODUCTS, INC. payments for restructuring for fiscal 2018 was $2.01M, a 156.78% increase from fiscal 2017.
| Period end | Payments for Restructuring 12 month | Payments for Restructuring 12 month as first filed |
|---|---|---|
| 2021-12-31 | $594.00K 10-K · filed 2022-03-08 | |
| 2020-12-31 | $840.00K 10-K · filed 2022-03-08 | |
| 2019-12-31 | $2.26M 10-K · filed 2021-03-10 | |
| 2018-12-31 | $2.01M 10-K · filed 2020-03-11 | |
| 2017-12-31 | $782.00K 10-K · filed 2019-03-08 | |
| 2016-12-31 | $995.00K 10-K · filed 2019-03-08 | $782.00K 10-K · filed 2018-03-16 |
| 2015-12-31 | $995.00K 10-K · filed 2018-03-16 | |
| 2014-12-31 | $2.46M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |